Бърз отговор
Nublexa — Regorafenib 40 mg (Bayer). Multikinase inhibitor for metastatic colorectal cancer after standard therapy failure, advanced GIST after imatinib/sunitinib failure, hepatocellular carcinoma after sorafenib failure.
Какво получавате с MedsBase:
- СЗО-GMP сертифициран производител
- Дискретна опаковка в обикновен плик
- Доставка по целия свят
- Оценено от над 1,400 клиенти (прочети ревюта)
📦 Гаранция за преизпращане: ако поръчката ви не е пристигнала в рамките на 20 работни дни след изпращане, я преизпращаме без допълнителни такси. Прочети политиката.
Защо да поръчвате от MedsBase
Nublexa ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
Tyrosine kinase inhibitors are oral targeted therapies. They require specialist initiation, ongoing therapeutic drug monitoring (where available), and management of class-specific toxicities. Adherence is critical — missed doses risk treatment failure. Most TKIs are CYP3A4 substrates with major drug interactions.
FDA black-box for severe and fatal hepatotoxicity. Baseline + every 2 weeks LFTs first 2 months. Hand-foot skin reaction is dose-limiting (very common). Hypertension, fatigue, diarrhoea also common.
Често задавани въпроси
What is a TKI?
Tyrosine kinase inhibitors block specific signalling pathways driving cancer cell growth. Each TKI is selective for different targets (EGFR for gefitinib/erlotinib; multikinase for sorafenib/sunitinib; BCR-ABL for nilotinib/imatinib; BTK for ibrutinib; JAK for ruxolitinib; CDK4/6 for palbociclib).
Странични ефекти?
Class signature: rash (often correlates with response in EGFR inhibitors), diarrhoea, fatigue, hand-foot skin reaction, hypertension (multikinase), hepatotoxicity, QT prolongation. Each TKI has a specific profile.
Лекарствени взаимодействия?
Most TKIs are CYP3A4 substrates. Strong inhibitors (azoles, macrolides, ritonavir, grapefruit) raise levels and toxicity; strong inducers (rifampicin, phenytoin, carbamazepine, St John’s wort) drop levels and risk treatment failure.
Take with food?
Some TKIs (lapatinib, erlotinib) on empty stomach (food increases bioavailability variably). Others (gefitinib, sorafenib) with or without food. Specific instruction depends on the molecule — confirm with prescribing oncologist.
What about response monitoring?
Imaging (CT/MRI/PET) every 2-3 months early; tumour markers if applicable. Treatment continues while benefit; switch on progression or unacceptable toxicity.
Резистентност?
TKI resistance develops over time (typically 9-18 months in solid tumours). Mechanisms: target mutations (T790M for EGFR, T315I for BCR-ABL), alternate pathway activation, target overexpression. Next-generation TKIs (osimertinib, ponatinib) overcome specific resistance mutations.
Какво да направя, ако пропусна доза?
Take when you remember if same day if >6 hours from next dose. Otherwise skip — do not double up. Specific instructions vary by drug; confirm with your oncology team.
Бременност?
All TKIs are teratogenic — effective contraception during and for at least 4-6 months after for both partners.
Cardiac monitoring?
Multikinase TKIs (sorafenib, sunitinib): BP monitoring, ECG (QT), echocardiogram in selected cases. BCR-ABL TKIs (nilotinib): mandatory ECG at baseline and follow-up — QT prolongation.
Cost-effectiveness?
Generic TKIs are widely manufactured under voluntary licences in India and other jurisdictions. Indian generic prices are dramatically lower than branded equivalents. Quality and bioequivalence are well-documented.
Other Cancer Medications
- Xeloda — capecitabine 500 mg — oral 5-FU prodrug for breast/colorectal/gastric cancers
- Altraz — anastrozole 1 mg — aromatase inhibitor for post-menopausal breast cancer
- Xbira — abiraterone 250 mg — CYP17 inhibitor for metastatic prostate cancer
- Zoldria — zoledronic acid IV — for bone metastases and hypercalcaemia
- Actorise — darbepoetin alfa — for chemotherapy-induced anaemia

























Отзиви
Все още няма отзиви